Heart Transplantation and Risk of Cardiac Vasculopathy Development: What Factors Are Important?
- PMID: 29146891
- PMCID: PMC6248309
- DOI: 10.12659/aot.905267
Heart Transplantation and Risk of Cardiac Vasculopathy Development: What Factors Are Important?
Abstract
BACKGROUND The aim of this study was to find the main risk factors for development of cardiac allograft vasculopathy (CAV), especially factors identified before the surgical procedure and factors related to the recipient profile and the medical history of the donor. MATERIAL AND METHODS There were 147 patients who had heart transplantation (HT) included in this study: mean age was 45.8±15.3 years. All study patients had coronary angiography after HT. Analyzed risk factors were: non-immunologic recipient risk factors (age of transplantation, smoking, hypertension, lipids, diabetes, obesity and weight gain after HT), immunologic recipient risk factors (acute cellular rejection (ACR), acute humoral rejection (AMR), cytomegalovirus (CMV) episodes), and donor-related risk factors (age, sex, catecholamine usage, ischemic time, compatibility of sex and blood groups, cause of death, cardiac arrest). RESULTS CAV was recognized in 48 patients (CAV group); mean age 53.6±13.6 years. There were 99 patients without CAV (nonCAV group); mean age 48.3±15.5 years. A univariate Cox analysis of the development of coronary disease showed statistical significance (p<0.05) for baseline high-density lipid (HDL), ACR, AMR, CMV, and donor age. Multivariate Cox regression model confirmed that only baseline HDL, episodes of ACR, donor age, and CMV infection are significant for the frequency of CAV after HT. CONCLUSIONS Older donor age is highly associated with CAV development. Older donor age and low level of HDL in heart recipients with the strongest influence of immunologic risk factors (ACR, CMV infection) were linked with development of CAV.
Conflict of interest statement
None.
Figures



Similar articles
-
Epicardial fat volume is related to the degree of cardiac allograft vasculopathy.Eur Radiol. 2023 Jan;33(1):330-338. doi: 10.1007/s00330-022-09029-2. Epub 2022 Aug 20. Eur Radiol. 2023. PMID: 35986769 Free PMC article.
-
Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy.Transplantation. 2003 Aug 27;76(4):679-82. doi: 10.1097/01.TP.0000071200.37399.1D. Transplantation. 2003. PMID: 12973108
-
The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.Transplantation. 2020 Jul;104(7):1508-1518. doi: 10.1097/TP.0000000000003015. Transplantation. 2020. PMID: 31644496 Free PMC article.
-
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.J Heart Lung Transplant. 2004 May;23(5 Suppl):S187-93. doi: 10.1016/j.healun.2004.03.009. J Heart Lung Transplant. 2004. PMID: 15093804 Review.
-
Optimizing the immunosuppressive regimen in heart transplantation.J Heart Lung Transplant. 2004 May;23(5 Suppl):S207-13. doi: 10.1016/j.healun.2004.03.010. J Heart Lung Transplant. 2004. PMID: 15093807 Review.
Cited by
-
A Clinical Model to Predict the Occurrence of Select High-risk Infections in the First Year Following Heart Transplantation.Transplant Direct. 2023 Nov 2;9(12):e1542. doi: 10.1097/TXD.0000000000001542. eCollection 2023 Dec. Transplant Direct. 2023. PMID: 37928481 Free PMC article.
-
Influence of donor age and donor-recipient age difference on intimal hyperplasia in pediatric patients with young and adult donors vs. adult patients after heart transplantation.Clin Res Cardiol. 2024 Jun 24. doi: 10.1007/s00392-024-02477-4. Online ahead of print. Clin Res Cardiol. 2024. PMID: 38913171
-
Investigation of the Role of Oxidative Stress and Factors Associated with Cardiac Allograft Vasculopathy in Patients after Heart Transplantation.Oxid Med Cell Longev. 2020 Sep 15;2020:7436982. doi: 10.1155/2020/7436982. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33014277 Free PMC article.
-
Incidence, Risk Factors and Clinical Implications of Glucose Metabolic Changes after Heart Transplant.Biomedicines. 2022 Oct 26;10(11):2704. doi: 10.3390/biomedicines10112704. Biomedicines. 2022. PMID: 36359224 Free PMC article.
-
Extracellular Vesicle-Associated TWEAK Contributes to Vascular Inflammation and Remodeling During Acute Cellular Rejection.JACC Basic Transl Sci. 2023 Jan 11;8(5):439-456. doi: 10.1016/j.jacbts.2022.09.014. eCollection 2023 May. JACC Basic Transl Sci. 2023. PMID: 37325400 Free PMC article.
References
-
- Roussel JC, Baron O, Perigaud C, et al. Outcome of heart transplants 15 to 20 years ago: Graft survival, post-transplant morbidity, and risk factors for mortality. J Heart Lung Transplant. 2008;27:486–93. - PubMed
-
- Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of standardized nomenclature for cardiac allograft vasculopathy – 2010. J Heart Lung Transplant. 2010;29:717–27. - PubMed
-
- Rodriguez ER. The pathology of heart transplant biopsy specimens: Revisiting the 1990 ISHLT Working Formulation. J Heart Lung Transplant. 2003;22:3–15. - PubMed
-
- Stewart S, Winters GL, Fisbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplantation. 2005;24:1710–20. - PubMed
-
- Kotton CN, Kumar D, Caliendo AM, et al. International Consensus Guidelines on the management of cytomagalovirus in solid organ transplantation. Transplantation. 2010;89:779–95. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical